Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh; Kyung Hee Lee; Sun Young Rha; Yasutsuna Sasaki; Se Hoon Park; Yoshito Komatsu; Hirofumi Yasui; Tae You Kim; Kensei Yamaguchi; Nozomu Fuse; Yasuhide Yamada; Takashi Ura; Si Young Kim; Masaki Munakata; Soh Saitoh; Kazuto Nishio; Satoshi Morita; Eriko Yamamoto; Qingwei Zhang; Jung mi Kim; Yeul Hong Kim; Yuh Sakata

doi:10.1007/s10120-014-0420-9

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Taroh Satoh, Kyung Hee Lee, Sun Young Rha, Yasutsuna Sasaki, Se Hoon Park, Yoshito Komatsu, Hirofumi Yasui, Tae You Kim, Kensei Yamaguchi, Nozomu Fuse, Yasuhide Yamada, Takashi Ura, Si Young Kim, Masaki Munakata, Soh Saitoh, Kazuto Nishio, Satoshi Morita, Eriko Yamamoto, Qingwei Zhang, Jung mi KimYeul Hong Kim, Yuh Sakata

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

Background: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Methods: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m² biweekly) or IRI (irinotecan 150 mg/m² biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Results: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. Conclusions: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.

Original language	English
Pages (from-to)	824-832
Number of pages	9
Journal	Gastric Cancer
Volume	18
Issue number	4
DOIs	https://doi.org/10.1007/s10120-014-0420-9
Publication status	Published - 2015 Oct 25

Bibliographical note

Funding Information:
We thank all the patients, their families, and the institutions involved in this study. The authors also thank the following individual board members for their contributions to this report: Independent Data Monitoring Committee, Keiichi Nagao, Noriyuki Masuda, Ichinosuke Hyodo, Baek-Yeol Ryoo, Young Iee Park, and Hong Suk Song; Efficacy Evaluation Committee, Atsushi Sato, Junji Tanaka, and Dae Young Zang; and Medical Advisors, Yutaka Ariyoshi and Kiyohiko Hatake. This trial was supported by a grant from Daiichi Sankyo Co., Ltd., Japan, and Kuhnil Pharm. Co., Ltd., Republic of Korea.

Funding Information:
T. Satoh, Y. Komatsu, Y. Yamada, and M. Munakata received research funding and honoraria from Daiichi Sankyo. Y.H. Kim received research funding and an honorarium from Kuhnil Pharm. K. Yamaguchi, N. Fuse, T. Ura, and S. Saitoh received research funding from Daiichi Sankyo. H. Yasui and S. Morita received honoraria from Daiichi Sankyo. Y. Sasaki, K. Nishio, and Y. Sakata received research funding, honoraria, and expert testimony from Daiichi Sankyo. K.H. Lee, S.Y. Rha, S.H. Park, T.Y. Kim, and S.Y. Kim have no conflicts of interests to declare.

Publisher Copyright:
© 2014, The Author(s).

All Science Journal Classification (ASJC) codes

Oncology
Gastroenterology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10120-014-0420-9

Cite this

Satoh, T., Lee, K. H., Rha, S. Y., Sasaki, Y., Park, S. H., Komatsu, Y., Yasui, H., Kim, T. Y., Yamaguchi, K., Fuse, N., Yamada, Y., Ura, T., Kim, S. Y., Munakata, M., Saitoh, S., Nishio, K., Morita, S., Yamamoto, E., Zhang, Q., ... Sakata, Y. (2015). Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. Gastric Cancer, 18(4), 824-832. https://doi.org/10.1007/s10120-014-0420-9

@article{860ecbdb371840e3b75ec47ef34f6c4b,

title = "Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer",

abstract = "Background: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Methods: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly) or IRI (irinotecan 150 mg/m2 biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Results: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. Conclusions: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.",

author = "Taroh Satoh and Lee, {Kyung Hee} and Rha, {Sun Young} and Yasutsuna Sasaki and Park, {Se Hoon} and Yoshito Komatsu and Hirofumi Yasui and Kim, {Tae You} and Kensei Yamaguchi and Nozomu Fuse and Yasuhide Yamada and Takashi Ura and Kim, {Si Young} and Masaki Munakata and Soh Saitoh and Kazuto Nishio and Satoshi Morita and Eriko Yamamoto and Qingwei Zhang and Kim, {Jung mi} and Kim, {Yeul Hong} and Yuh Sakata",

note = "Funding Information: We thank all the patients, their families, and the institutions involved in this study. The authors also thank the following individual board members for their contributions to this report: Independent Data Monitoring Committee, Keiichi Nagao, Noriyuki Masuda, Ichinosuke Hyodo, Baek-Yeol Ryoo, Young Iee Park, and Hong Suk Song; Efficacy Evaluation Committee, Atsushi Sato, Junji Tanaka, and Dae Young Zang; and Medical Advisors, Yutaka Ariyoshi and Kiyohiko Hatake. This trial was supported by a grant from Daiichi Sankyo Co., Ltd., Japan, and Kuhnil Pharm. Co., Ltd., Republic of Korea. Funding Information: T. Satoh, Y. Komatsu, Y. Yamada, and M. Munakata received research funding and honoraria from Daiichi Sankyo. Y.H. Kim received research funding and an honorarium from Kuhnil Pharm. K. Yamaguchi, N. Fuse, T. Ura, and S. Saitoh received research funding from Daiichi Sankyo. H. Yasui and S. Morita received honoraria from Daiichi Sankyo. Y. Sasaki, K. Nishio, and Y. Sakata received research funding, honoraria, and expert testimony from Daiichi Sankyo. K.H. Lee, S.Y. Rha, S.H. Park, T.Y. Kim, and S.Y. Kim have no conflicts of interests to declare. Publisher Copyright: {\textcopyright} 2014, The Author(s).",

year = "2015",

month = oct,

day = "25",

doi = "10.1007/s10120-014-0420-9",

language = "English",

volume = "18",

pages = "824--832",

journal = "Gastric Cancer",

issn = "1436-3291",

publisher = "Springer Japan",

number = "4",

}

Satoh, T, Lee, KH, Rha, SY, Sasaki, Y, Park, SH, Komatsu, Y, Yasui, H, Kim, TY, Yamaguchi, K, Fuse, N, Yamada, Y, Ura, T, Kim, SY, Munakata, M, Saitoh, S, Nishio, K, Morita, S, Yamamoto, E, Zhang, Q, Kim, JM, Kim, YH & Sakata, Y 2015, 'Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer', Gastric Cancer, vol. 18, no. 4, pp. 824-832. https://doi.org/10.1007/s10120-014-0420-9

TY - JOUR

T1 - Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

AU - Satoh, Taroh

AU - Lee, Kyung Hee

AU - Rha, Sun Young

AU - Sasaki, Yasutsuna

AU - Park, Se Hoon

AU - Komatsu, Yoshito

AU - Yasui, Hirofumi

AU - Kim, Tae You

AU - Yamaguchi, Kensei

AU - Fuse, Nozomu

AU - Yamada, Yasuhide

AU - Ura, Takashi

AU - Kim, Si Young

AU - Munakata, Masaki

AU - Saitoh, Soh

AU - Nishio, Kazuto

AU - Morita, Satoshi

AU - Yamamoto, Eriko

AU - Zhang, Qingwei

AU - Kim, Jung mi

AU - Kim, Yeul Hong

AU - Sakata, Yuh

N1 - Funding Information: We thank all the patients, their families, and the institutions involved in this study. The authors also thank the following individual board members for their contributions to this report: Independent Data Monitoring Committee, Keiichi Nagao, Noriyuki Masuda, Ichinosuke Hyodo, Baek-Yeol Ryoo, Young Iee Park, and Hong Suk Song; Efficacy Evaluation Committee, Atsushi Sato, Junji Tanaka, and Dae Young Zang; and Medical Advisors, Yutaka Ariyoshi and Kiyohiko Hatake. This trial was supported by a grant from Daiichi Sankyo Co., Ltd., Japan, and Kuhnil Pharm. Co., Ltd., Republic of Korea. Funding Information: T. Satoh, Y. Komatsu, Y. Yamada, and M. Munakata received research funding and honoraria from Daiichi Sankyo. Y.H. Kim received research funding and an honorarium from Kuhnil Pharm. K. Yamaguchi, N. Fuse, T. Ura, and S. Saitoh received research funding from Daiichi Sankyo. H. Yasui and S. Morita received honoraria from Daiichi Sankyo. Y. Sasaki, K. Nishio, and Y. Sakata received research funding, honoraria, and expert testimony from Daiichi Sankyo. K.H. Lee, S.Y. Rha, S.H. Park, T.Y. Kim, and S.Y. Kim have no conflicts of interests to declare. Publisher Copyright: © 2014, The Author(s).

PY - 2015/10/25

Y1 - 2015/10/25

N2 - Background: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Methods: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly) or IRI (irinotecan 150 mg/m2 biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Results: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. Conclusions: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.

AB - Background: This multicenter, randomized phase II trial was conducted to compare the efficacy and safety of nimotuzumab plus irinotecan (N-IRI) versus irinotecan alone (IRI) in patients with advanced gastric cancer (AGC) showing disease progression after previous 5-fluorouracil-based therapy. Methods: Irinotecan-naive patients (n = 82) received N-IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly) or IRI (irinotecan 150 mg/m2 biweekly) until disease progression. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were overall survival (OS), response rate (RR), safety, tolerability, and the correlation between efficacy and tumor epidermal growth factor receptor (EGFR) expression. Results: Of 83 patients, 40 and 43 patients were randomly assigned to the N-IRI and IRI groups, respectively. In the N-IRI/IRI treatment group, median PFS was 73.0/85.0 days (P = 0.5668), and median OS and RR at 18 months were 250.5/232.0 days (P = 0.9778) and 18.4/10.3 %, respectively. Median PFS and OS in the EGFR 2+/3+ subgroups were 118.5/59.0 and 358.5/229.5 days, respectively. The RR was 33.3/0.0 % in the N-IRI/IRI treatment group. The incidence of grade 3 or higher adverse events was 77.5/64.3 %. No adverse events of grade 3 or higher skin rash or grade 3 or higher infusion-related reaction were reported. Conclusions: There was no superiority of N-IRI over IRI alone in terms of PFS in 5-fluorouracil-refractory AGC patients. However, N-IRI showed potential improvement in the EGFR 2+/3+ subgroup based on improved RR, PFS, and OS.

UR - http://www.scopus.com/inward/record.url?scp=84942115572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942115572&partnerID=8YFLogxK

U2 - 10.1007/s10120-014-0420-9

DO - 10.1007/s10120-014-0420-9

M3 - Article

C2 - 25185971

AN - SCOPUS:84942115572

SN - 1436-3291

VL - 18

SP - 824

EP - 832

JO - Gastric Cancer

JF - Gastric Cancer

IS - 4

ER -

Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this